OncoTherapy Science, Inc. (TYO:4564)
Japan · Delayed Price · Currency is JPY 21.00
0.00 (0.00%)
Aug 27, 2026, 1:50 PM JST
OncoTherapy Science Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 777 | 808 | 750 | 610 | 1,134 | 1,153 | |
Revenue Growth | -8.70% | 7.73% | 22.95% | -46.21% | -1.65% | 247.29% |
Cost of Revenue | 1,276 | 1,329 | 1,253 | 1,465 | 1,810 | 2,770 |
Gross Profit | -499 | -521 | -503 | -855 | -676 | -1,617 |
Selling, General & Admin | 292 | 289 | 289 | 261 | 287 | 294 |
Other Operating Expenses | - | - | 5 | 4 | 144 | 142 |
Operating Expenses | 292 | 289 | 294 | 265 | 431 | 436 |
Operating Income | -791 | -810 | -797 | -1,120 | -1,107 | -2,053 |
Interest Expense | -1 | -1 | -1 | - | - | - |
Currency Exchange Gain (Loss) | -4 | -2 | 1 | -5 | -8 | -14 |
Other Non Operating Income (Expenses) | -22 | -32 | -18 | -12 | -18 | -5 |
EBT Excluding Unusual Items | -818 | -845 | -815 | -1,137 | -1,133 | -2,072 |
Asset Writedown | -64 | -63 | - | -154 | -21 | -547 |
Other Unusual Items | - | - | 2 | 5 | 38 | 49 |
Pretax Income | -882 | -908 | -813 | -1,286 | -1,116 | -2,570 |
Income Tax Expense | 2 | 2 | 2 | 2 | 2 | 1 |
Earnings From Continuing Operations | -884 | -910 | -815 | -1,288 | -1,118 | -2,571 |
Net Income | -884 | -910 | -815 | -1,288 | -1,118 | -2,571 |
Net Income to Common | -884 | -910 | -815 | -1,288 | -1,118 | -2,571 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 358 | 328 | 261 | 213 | 193 | 187 |
Shares Outstanding (Diluted) | 358 | 328 | 261 | 213 | 193 | 187 |
Shares Change | 31.59% | 25.69% | 22.73% | 10.45% | 2.76% | 6.31% |
EPS (Basic) | -2.47 | -2.77 | -3.12 | -6.05 | -5.80 | -13.71 |
EPS (Diluted) | -2.47 | -2.77 | -3.12 | -6.05 | -5.80 | -13.71 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -984 | -815 | -1,229 | -798 | -2,529 |
Free Cash Flow Per Share | - | -3.00 | -3.12 | -5.78 | -4.14 | -13.49 |
Gross Margin | -64.22% | -64.48% | -67.07% | -140.16% | -59.61% | -140.24% |
Operating Margin | -101.80% | -100.25% | -106.27% | -183.61% | -97.62% | -178.06% |
Profit Margin | -113.77% | -112.62% | -108.67% | -211.15% | -98.59% | -222.98% |
Free Cash Flow Margin | - | -121.78% | -108.67% | -201.47% | -70.37% | -219.34% |
EBITDA | - | - | - | - | -1,091 | -2,037 |
EBITDA Margin | - | - | - | - | -96.21% | -176.67% |
D&A For EBITDA | - | - | - | - | 16 | 16 |
EBIT | -791 | -810 | -797 | -1,120 | -1,107 | -2,053 |
EBIT Margin | -101.80% | -100.25% | -106.27% | -183.61% | -97.62% | -178.06% |